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An accidental liraglutide overdose: case report
L
iraglutide is a glucagon-like peptide 1 (GLP-1)
agonist that is 97% homologous to the endogen-
ous human GLP-1 (1). By mimicking the effects of
native GLP-1, it enhances the glucose-dependent secre-
tion of insulin from beta cells of pancreatic islets,
suppresses elevated glucagon secretion, and slows down
gastric emptying and increases satiety (2). It results in a
0.51.5% reduction in HbA1c (3) and can be used as a
monotherapy or as an add-on therapy to metformin,
sulfonylurea, thiazolinediones, and/or insulin (2). It was
approved by the European Medicines Agency in 2009 and
by the US Food and Drug Administration in 2010.
We report the case of a 49-year-old woman who
presented with an accidental liraglutide overdose. She
has type 2 diabetes treated with a prescribed metformin
850 mg t.d.s. liraglutide pen with a starting dose of
0.6 mg per day subcutaneously. Her most recent HbA1c
was 8.9%, and her body mass index was 41.6 kg/m2. On
the first day of liraglutide therapy, she mistakenly injected
the whole liraglutide pen by repeating the 0.6 mg dose
injection 30 times (total dose of 18 mg).
One hour later she developed nausea and vomiting
and her blood glucose at that time was 3.6 mmol/L. She
was admitted two and a half hours after the overdose
occurred.
She did not complain of abdominal pain but she was
severely nauseated and vomiting.
Her blood glucose on admission was 4.49 mmol/L.
In hospital, she was treated with intravenous fluids
and intravenous metoclopramide. Her liver function tests
and serum amylase levels remained within the normal
range. She was aferbril, and her blood pressure was
170/100 mm Hg.
Her nausea improved and vomiting stopped 13 hours
after the overdose  she vomited a total of 19 times. Her
blood glucose during admission ranged from 4.49 to
12.93 mmol/L (mean 10.192.23 mmol/L).
She was discharged 24 hours after admission. For the
next five days, the patient felt mildly nauseous and had
excessive belching but no abdominal pain; her blood
glucose ranged from 6.6 to 9.76 mmol/L without any
anti-hyperglycemic therapy. On Day 7, the patient’s blood
glucose started rising and she restarted her metfromin
treatment.
Few cases of liraglutide overdose are reported in the
literature (46). Severe nausea and vomiting and occa-
sional abdominal pain and diarrhea are the only reported
symptoms (46). In none of the reported cases did
hypoglycemia occur even when the administered dose
was massive (72 mg) (5) or the overdose was continued
for a long time (seven months) (6). There was no incident
of pancreatitis, and the treatment is mainly supportive
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